IP Library › Granted Patent US 12,186,310
Granted Patent B2
US 12,186,310 · App. 18/117,089 · Granted Jan 7, 2025

Antibody-drug conjugate

Inventors: Takeshi Masuda (Tokyo, JP); Hiroyuki Naito (Tokyo, JP); Takashi Nakada (Tokyo, JP); Masao Yoshida (Tokyo, JP); Shinji Ashida (Tokyo, JP); Hideki Miyazaki (Tokyo, JP); Yuji Kasuya (Tokyo, JP); Koji Morita (Tokyo, JP); Yuki Abe (Tokyo, JP); Yusuke Ogitani (Tokyo, JP)
Assignee: DAIICHI SANKYO COMPANY, LIMITED
A61K31/4745A61K31/48A61K47/68037C07K16/2803C07K16/2827C07K16/2851C07K16/2875C07K16/2878C07K16/30C07K2317/30C07K2317/77
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,186,310
App. No.
18/117,089
Granted
Jan 7, 2025
Kind
B2
Abstract

As an antitumor drug which is excellent in terms of antitumor effect and safety, there is provided an antibody-drug conjugate in which an antitumor compound represented by the following formula is conjugated to an antibody via a linker having a structure represented by the following formula: -L 1 -L 2 -L P -NH—(CH 2 )n 1 -L a -L b -L c - wherein the antibody is connected to the terminal of L 1 , and the antitumor compound is connected to the terminal of L c with the nitrogen atom of the amino group at position 1 as a connecting position.

Claims (1)

1. A compound of the following formula:

Priority Claims (1)
JP 2012-225887 · Oct 11, 2012 · national
Continuity (4)
Continuation 16828279 · Mar 24, 2020
Continuation 16142354 · Sep 26, 2018
Continuation 14435114
Related Publication 20240082413A1 · Mar 14, 2024
References Cited (163)
US 5834476A · Terasawa et al. · 1998 [cited by applicant]
US 5837673A · Tsujihara et al. · 1998 [cited by applicant]
US 6214345B1 · Firestone et al. · 2001 [cited by applicant]
US 6291671B1 · Inoue et al. · 2001 [cited by applicant]
US 6835807B1 · Susaki et al. · 2004 [cited by applicant]
US 7041818B2 · Susaki et al. · 2006 [cited by applicant]
US 7585491B2 · Govindan · 2009 [cited by applicant]
US 7833979B2 · Sullivan et al. · 2010 [cited by applicant]
US 7837980B2 · Alley et al. · 2010 [cited by applicant]
US 8226945B2 · Ebens, Jr. et al. · 2012 [cited by applicant]
US 8268319B2 · Govindan · 2012 [cited by applicant]
US 8394607B2 · Ebens, Jr. et al. · 2013 [cited by applicant]
US 8425912B2 · Govindan · 2013 [cited by applicant]
US 8524865B2 · Ebens, Jr. et al. · 2013 [cited by applicant]
US 8574575B2 · Govindan et al. · 2013 [cited by applicant]
US 8741291B2 · Bhat et al. · 2014 [cited by applicant]
US 8907071B2 · Sullivan et al. · 2014 [cited by applicant]
US 8968741B2 · Ebens et al. · 2015 [cited by applicant]
US 9872924B2 · Naito et al. · 2018 [cited by applicant]
US 10729782B2 · Naito et al. · 2020 [cited by applicant]
US 11795236B2 · Naito et al. · 2023 [cited by applicant]
US 20030148931A1 · Takahashi et al. · 2003 [cited by applicant]
US 20030166513A1 · Imura et al. · 2003 [cited by applicant]
US 20040185053A1 · Govindan · 2004 [cited by applicant]
US 20040192644A1 · Susaki et al. · 2004 [cited by applicant]
US 20050123536A1 · Law et al. · 2005 [cited by applicant]
US 20050228007A1 · Jagtap et al. · 2005 [cited by applicant]
US 20050271671A1 · Griffith · 2005 [cited by applicant]
US 20050276812A1 · Ebens et al. · 2005 [cited by applicant]
US 20060193865A1 · Govindan · 2006 [cited by applicant]
US 20060275305A1 · Bryant · 2006 [cited by applicant]
US 20070071764A1 · Sullivan et al. · 2007 [cited by applicant]
US 20080050310A1 · Ebens, Jr. et al. · 2008 [cited by applicant]
US 20080161245A1 · Kratz et al. · 2008 [cited by applicant]
US 20080305044A1 · McDonagh et al. · 2008 [cited by applicant]
US 20090274713A1 · Chari et al. · 2009 [cited by applicant]
US 20090291093A1 · Govindan · 2009 [cited by applicant]
US 20100068181A1 · Paliwal et al. · 2010 [cited by applicant]
US 20100120816A1 · Fontana et al. · 2010 [cited by applicant]
US 20110045587A1 · Sullivan et al. · 2011 [cited by applicant]
US 20110070248A1 · Ichikawa et al. · 2011 [cited by applicant]
US 20110293513A1 · Govindan et al. · 2011 [cited by applicant]
US 20120052076A1 · Alberti et al. · 2012 [cited by applicant]
US 20120121615A1 · Flygare et al. · 2012 [cited by applicant]
US 20120201809A1 · Bhat et al. · 2012 [cited by applicant]
US 20120328634A1 · Govindan · 2012 [cited by applicant]
US 20130122020A1 · Liu et al. · 2013 [cited by applicant]
US 20130123178A1 · Dimarchi et al. · 2013 [cited by applicant]
US 20130216561A1 · Govindan · 2013 [cited by applicant]
US 20140004078A1 · Govindan · 2014 [cited by applicant]
US 20150352224A1 · Naito et al. · 2015 [cited by applicant]
US 20160287722A1 · Govindan · 2016 [cited by applicant]
US 20180071403A1 · Naito et al. · 2018 [cited by applicant]
CA 2927832A1 · 2011 [cited by applicant]
CA 2859255A1 · 2013 [cited by applicant]
CN 1764478A · 2006 [cited by applicant]
CN 101490087A · 2009 [cited by applicant]
EP 0495432A1 · 1992 [cited by applicant]
EP 0737686A1 · 1996 [cited by applicant]
EP 0781781A2 · 1997 [cited by applicant]
EP 0916348A1 · 1999 [cited by applicant]
EP 1155702A1 · 2001 [cited by applicant]
JP H05059061A · 1993 [cited by applicant]
JP H0687746A · 1994 [cited by applicant]
JP H08337584A · 1996 [cited by applicant]
JP H10095802A · 1998 [cited by applicant]
JP H1171280A · 1999 [cited by applicant]
JP H11092405A · 1999 [cited by applicant]
JP 2002060351A · 2002 [cited by applicant]
JP 2005511627A · 2005 [cited by applicant]
JP 2006511526A · 2006 [cited by applicant]
JP 2007527872A · 2007 [cited by applicant]
JP 2008521828A · 2008 [cited by applicant]
JP 2009538629A · 2009 [cited by applicant]
JP 2010513524A · 2010 [cited by applicant]
JP 2012100671A · 2012 [cited by applicant]
JP 2013534535A · 2013 [cited by applicant]
JP 2013534906A · 2013 [cited by applicant]
RU 2450008C2 · 2010 [cited by applicant]
RU 2404810C2 · 2010 [cited by applicant]
TW I232930 · 2005 [cited by applicant]
TW 200817434A · 2008 [cited by applicant]
WO WO9746260A1 · 1997 [cited by applicant]
WO WO0025825A1 · 2000 [cited by applicant]
WO WO0200734A1 · 2002 [cited by applicant]
WO WO03015826A1 · 2003 [cited by applicant]
WO WO03043583A2 · 2003 [cited by applicant]
WO WO2005112919A2 · 2005 [cited by applicant]
WO WO2006065533A2 · 2006 [cited by applicant]
WO WO2006092230A2 · 2006 [cited by applicant]
WO WO2008116219A2 · 2008 [cited by applicant]
WO WO2011021397A1 · 2011 [cited by applicant]
WO WO2013163229A1 · 2013 [cited by applicant]
WO WO2013188740A1 · 2013 [cited by applicant]
WO WO2014057687A1 · 2014 [cited by applicant]
WO WO2014061277A1 · 2014 [cited by applicant]
WO WO2014107024A1 · 2014 [cited by applicant]
Acchione et al., “Impact of linker and conjugation chemistry on antigen binding, Fc receptor binding and thermal stability of model antibody-drug conjugates,” mAbs, vol. 4, No. 3, May/Jun. 2012, pp. 362-372. [cited by applicant]
Alley et al., “Antibody-drug conjugates: targeted drug delivery for cancer,” Current Opinion in Chemical Biology, vol. 14, 2010, pp. 529-537. [cited by applicant]
“Appeal for Reposition against Resolution 12260 of Feb. 21 of 2018, by which a patent of invention is granted,” filed in Colombian Patent Office in connection with Colombian Patent Application No. NC2016/0000187. [cited by applicant]
Barginear et al., “Trastuzumab-DM1: A Review of the Novel Immuno-Conjugate for HER2-Overexpressing Breast Cancer,” The Open Breast Cancer Journal, vol. 1, 2009, pp. 25-30. [cited by applicant]
Barok et al., “Trastuzumab-DM1 is highly effective in preclinical models of HER2-positive gastric cancer,” Cancer Letters, vol. 306, 2011, pp. 172-179. [cited by applicant]
Beck, Alain, “The Next Generation of Antibody-drug Conjugates Comes of Age,” Discovery Medicine, vol. 10, No. 53, Oct. 16, 2010 (8 pages). [cited by applicant]
Behrens et al., “Methods for site-specific drug conjugation to antibodies,” mAbs, vol. 6, No. 1, 2014, pp. 46-53. [cited by applicant]
Burke et al., “Design, Synthesis, and Biological Evaluation of Antibody-Drug Conjugates Comprised of Potent Camptothecin Analogues”, Bioconjugate Chemistry, vol. 20, No. 6, 2009, pp. 1242-1250. [cited by applicant]
Canadian Intellectual Property Office, “Interview Summary,” issued in connection with Canadian Patent Application No. 2,885,800, dated Mar. 28, 2017. [cited by applicant]
Canadian Intellectual Property Office, “Office Action,” issued in connection with Canadian Patent Application No. 2,939,802, dated Apr. 13, 2018. [cited by applicant]
Damle, Nitin K., “Tumour-targeted chemotherapy with immunoconjugates of calicheamicin,” Expert Opin. Biol. Ther., vol. 4, No. 9, 2004, pp. 1445-1452. [cited by applicant]
De Jager et al., “DX-8951f: Summary of Phase I Clinical Trials,” Ann. N.Y. Acad. Sci., vol. 922, 2000, pp. 260-273. [cited by applicant]
Dosio et al., “Antibody-targeted leucinostatin A”, Journal of Controlled Release, No. 32, (1994), pp. 37-44. [cited by applicant]
Ducry et al., “Antibody—Drug Conjugates: Linking Cytotoxic Payloads to Monoclonal Antibodies,” Bioconjugate Chem, vol. 21, 2010, pp. 5-13. [cited by applicant]
European Patent Office, “Communication with extended European Search Report,” issued in connection with European Patent Application No. 13845596.9, dated May 6, 2016. [cited by applicant]
European Patent Office, “Communication with extended European Search Report,” issued in connection with European Patent Application No. 13847461.4, dated May 13, 2016. [cited by applicant]
European Patent Office, “Extended European Search Report,” issued in connection with European Patent Application No. 19206764.3., dated Feb. 4, 2020. [cited by applicant]
European Search Report issued in corresponding application No. 14874745.4 dated May 10, 2017. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 15743738.5 dated Aug. 9, 2017. [cited by applicant]
Extended European Search Report issued in European Patent Application No. 15776810.2 dated Aug. 11, 2017. [cited by applicant]
Gomez-Monterrey et al., “Design, Synthesis, and Cytotoxic Evaluation of Acyl Derivatives of 3-Aminonaphtho[2,3-b]thiophene-4,9-dione, a Quinone-Based System,” Journal of Medicinal Chemistry, 2011, 54(12):4077-4091, abst… [cited by applicant]
Inoue et al., “CM-Dextran-Polyalcohol-Camptothecin Conjugate: DE-310 with a Novel Carrier System and Its Preclinical Data,” Polymer Drugs in the Clinical Stage, 2003, pp. 145-153. [cited by applicant]
Intellectual Property Office of Singapore, “Invitation to Respond to Written Opinion,” issued in connection with Singaporean Patent Application No. 11201502887W, dated Apr. 22, 2016. [cited by applicant]
International Searching Authority, “International Search Report,” issued in connection with International Patent Application No. PCT/JP2013/006069, dated Dec. 17, 2013. [cited by applicant]
International Searching Authority, “International Search Report,” issued in connection with International Patent Application No. PCT/JP2013/006178, dated Dec. 17, 2013. [cited by applicant]
Japanese Patent Office, “Decision to Grant a Patent,” in connection with Japanese Patent Application No. 2016-166850, dated Oct. 18, 2016. [cited by applicant]
Japanese Patent Office, “Decision to Grant Patent,” issued in connection with Japanese Patent Application No. 2016-117096, dated Jul. 4, 2017. [cited by applicant]
Japanese Patent Office, “Notification of Reasons for Refusal,” in connection with Japanese Patent Application No. 2016-540705, dated Dec. 6, 2016. [cited by applicant]
Joto et al., “DX-8951F, A Water-Soluble Camptothecin Analog, Exhibits Potent Antitumor Activity Against a Human Lung Cancer Cell Line and its SN-38-Resistant Variant,” Int. J. Cancer, vol. 72, 1997, pp. 680-686. [cited by applicant]
Kumazawa et al., “Antitumor activity of DX-8951f: a new camptothecin derivative,” Exp. Opin. Invest. Drugs 7(4):625-632 (1998). [cited by applicant]
Kumazawa et al., “DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f: Potent antitumor activities in various murine tumor models,” Cancer Sci., vol. 95, No. 2, Feb. 2004, pp. 168-175. [cited by applicant]
Kumazawa et al., “Potent and broad antitumor effects of DX-8951f, a water-soluble camptothecin derivative, against various human tumors xenografted in nude mice,” Cancer Chemother. Pharmacol., vol. 42, 1998, pp. 210-220. [cited by applicant]
Loo et al., “Development of an Fc-Enhanced Anti-B7-H3 Monoclonal Antibody with Potent Antitumor Activity,” Clinical Cancer Research, vol. 18, No. 4, Jul. 15, 2012, pp. 3834-3845. [cited by applicant]
Masubuchi, N., “Pharmacokinetics of DE-310, a novel macromolecular carrier system for the camptothecin analog DX-8951f, in tumor-bearing mice,” Pharmazie, vol. 59, No. 5, 2004, pp. 374-377. [cited by applicant]
Mcdonagh et al., “Engineered antibody-drug conjugates with defined sites and stoichiometries of drug attachment,” Protein Engineering, Design & Selection, 2006, 19(7):299-307. [cited by applicant]
Mitsui et al., “A New Water-soluble Camptothecin Derivative, DX-8951f, Exhibits Potent Antitumor Activity against Human Tumors in vitro and in vivo,” Jpn. J. Cancer Res, vol. 86, Aug. 1995, pp. 776-782. [cited by applicant]
Nakada et al., “Novel antibody drug conjugates containing exatecan derivative-based cytotoxic payloads,” Bioorganic & Medicinal Chemistry Letters, vol. 26, 2016, pp. 1542-1545. [cited by applicant]
Ochi et al., “A possible mechanism for the long-lasting antitumor effect of the macromolecular conjugate DE-310: mediation by cellular uptake and drug release of its active camptothecin analog DX-8951,” Cancer Chemother… [cited by applicant]
Office Action with Search Report dated Aug. 29, 2017, in RU 2015113767. [cited by applicant]
Oguma et al., “Validation study of a method for assaying DE-310, a macromolecular carrier conjugate containing an anti-tumor camptothecin derivative, and the free drug in tumor tissue by high performance liquid chromato… [cited by applicant]
Opposition dated May 9, 2017, against CO NC2016/0000187, with partial English translation. [cited by applicant]
Rowinsky et al., “Preclinical and Clinical Development of Exatecan (DX-8951f), [cited by applicant]
Russian Office Action dated Oct. 11, 2018 in corresponding application No. 2016123597. [cited by applicant]
Russian Office Action dated Mar. 5, 2019 in corresponding application No. 2016143351. [cited by applicant]
Senter et al., “The discovery and development of brentuximab vedotin for use in relapsed Hodgkin lymphoma and systemic anaplastic large cell lymphoma,” Nature Biotechnology, vol. 30, No. 7, Jul. 2012, pp. 631-637. [cited by applicant]
Shen et al., “Conjugation site modulates the in vivo stability and therapeutic activity of antibody-drug conjugates,” Nature Biotechnology, vol. 30, Jan. 22, 2012, pp. 184-189. [cited by applicant]
Shiose et al., “Systematic Research of Peptide Spacers Controlling Drug Release from Macromolecular Prodrug System, Carboxymethyldextran Polyalcohol-Peptide-Drug Conjugates,” Bioconjugate Chem., vol. 20, 2009, pp. 60-70. [cited by applicant]
Shiose et al., “Relationship between Drug Release of DE-310, Macromolecular Prodrug of DX-8951f, and Cathepsins Activity in Several Tumors,” Biol. Pharm. Bull., 2007, 30(12):2365-2370. [cited by applicant]
Sievers et al., “Antibody-Drug Conjugates in Cancer Therapy,” Annual Review of Medicine, vol. 64, 2013, pp. 15-29. [cited by applicant]
Soepenberg et al., “Liquid chromatographic assays for DE-310, a novel camptothecin analog, and two major enzymatic products in human matrices,” Journal of Chromatography B, vol. 799, 2004, pp. 15-22. [cited by applicant]
Taiwanese Office Action dated Jul. 30, 2018 in corresponding application No. 104111534. [cited by applicant]
Taiwanese Office Action dated May 15, 2017 in corresponding application No. 102136742. [cited by applicant]
Takiguchi et al., “Antitumor Effect of DX-8951, a Novel Camptothecin Analog, on Human Pancreatic Tumor Cells and Their CPT-11-resistant Variants Cultured in vitro and Xenografted in Nude Mice,” Jpn. J. Cancer Res., vol.… [cited by applicant]
The State Intellectual Property Office of People's Republic of China, “The First Office Action,” issued in connection with Chinese Patent Application No. 201380053256.2, dated Nov. 1, 2016. [cited by applicant]
The State Intellectual Property Office of People's Republic of China, “The First Office Action,” issued in connection with Chinese Patent Application No. 201480071134.0, dated Aug. 20, 2019. [cited by applicant]
Wente et al., “DE-310, a macromolecular prodrug of the topoisomerase-I-inhibitor exatecan (DX-8951), in patients with operable solid tumors,” Investigational New Drugs, vol. 23, 2005, pp. 339-347. [cited by applicant]
Office Action dated Apr. 16, 2021, for corresponding Brazilian Patent Application No. BR112015006521-0. [cited by applicant]
Office Action dated Sep. 16, 2021, for corresponding Australian Patent Application No. 2020200548 (15 pages). [cited by applicant]
Russian Office Action dated Dec. 20, 2021, from application No. 2018128384 (4 pages). [cited by applicant]
Lin et al., “A novel human Fab antibody for Trop2 inhibits breast cancer growth in vitro and in vivo” International Journal of Cancer, vol. 134, Aug. 26, 2013, pp. 1239-1249. [cited by applicant]
Office Action issued in corresponding Israeli Patent Application No. 291446 dated Nov. 20, 2023 (9 pages). [cited by applicant]
Raji et al., “Uterine and ovarian carcinosarcomas overexpressing Trop-2 are sensitive to hRS7, a humanized anti-Trop-2 antibody”, Journal of Experimental & Clinical Cancer Research, vol. 30, Nov. 10, 2011, pp. 1-7. [cited by applicant]
Wheeler et al., “Glycine: a new anti-inflammatory immunonutrient”, Cellular and Molecular Life Sciences, vol. 56, Aug. 17, 1999, pp. 843-856. [cited by applicant]
Riott et al., “Mir”, Immunology, Moscow, 2000, p. 153. [cited by applicant]
Search Report issued in corresponding Russian Patent Application No. 2021103152 dated Jul. 8, 2024 (2 pages). [cited by applicant]
Office Action issued in corresponding Egyptian Patent Application No. PCT1073/2016 dated Jul. 2, 2024 (6 pages). [cited by applicant]